Hologic, Inc. logo
Hologic, Inc. (HOLX)
Compare

Hologic, Inc. (HOLX) EV/Sales Ratio: 4.25x

Is Hologic, Inc.’s EV/Sales ratio high or low?

Hologic, Inc.'s EV/Sales ratio of 4.25x is in line with its 5-year average of 4.15x, around the middle of its 5-year range (3.04x–5.24x).

As of Thursday, June 11, 2026. 5.84% above its 12-month average of 4.02x.

HOLX EV/Sales Ratio Chart

HOLX EV/Sales Ratio
4.25x+14.56% 1Y
Zoom

HOLX Average EV/Sales Ratio Chart

HOLX Current vs Average EV/Sales Ratio Chart

HOLX EV/Sales Ratio Metrics

EV/SALES RATIO

4.25x

EV/SALES RATIO AVG TTM

4.02x

EV/SALES RATIO AVG 3Y

4.39x

EV/SALES RATIO AVG 5Y

4.15x

EV/SALES RATIO AVG 10Y

4.50x

EV/SALES RATIO AVG 15Y

4.39x

EV/SALES RATIO AVG 20Y

4.41x

CURRENT VS TTM AVG

+5.84%

CURRENT VS 3Y AVG

-3.21%

CURRENT VS 5Y AVG

+2.31%

CURRENT VS 10Y AVG

-5.55%

CURRENT VS 15Y AVG

-3.09%

CURRENT VS 20Y AVG

-3.73%

HOLX Competitors' EV/Sales Ratio

NAMEMARKET CAPEV/SALES RATIOTTM3Y5Y
Hologic, Inc. (HOLX)$16.97B4.25x4.02x4.39x4.15x
Moderna, Inc. (MRNA)$18.71B8.10x5.96x5.02x6.82x
Align Technology, Inc. (ALGN)$12.27B2.75x2.73x4.07x5.91x
BioNTech SE (BNTX)$22.39B3.24x4.19x3.71x3.49x
Mettler-Toledo International Inc. (MTD)$22.82B6.13x7.35x7.51x8.18x
Waters Corporation (WAT)$23.21B9.27x7.03x7.13x7.32x
Baxter International Inc. (BAX)$10.49B1.60x1.72x2.17x2.64x
Charles River Laboratories International, Inc. (CRL)$8.94B2.97x2.79x3.02x3.79x
Bio-Rad Laboratories, Inc. (BIO)$7.92B3.41x3.41x3.67x4.57x
Veeva Systems Inc. (VEEV)$26.31B7.65x12.50x13.33x15.70x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

  • It works for unprofitable companies where P/E doesn't apply
  • Revenue is harder to manipulate than earnings
  • It supports comparisons across companies at different profitability stages
  • It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

Hologic, Inc. EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Hologic, Inc. EV/Sales Ratio FAQ

What is the EV/Sales ratio for Hologic, Inc. (HOLX)?
The EV/Sales ratio for HOLX stock is 4.25x.
Is Hologic, Inc.'s EV/Sales ratio high or low?
Hologic, Inc.'s EV/Sales ratio of 4.25x is in line with its 5-year average of 4.15x, around the middle of its 5-year range (3.04x–5.24x).
What is the TTM average EV/Sales ratio for Hologic, Inc. (HOLX)?
The TTM average EV/Sales ratio for HOLX stock is 4.02x.
What is the 3Y average EV/Sales ratio for Hologic, Inc. (HOLX)?
The 3Y average EV/Sales ratio for HOLX stock is 4.39x.
What is the 5Y average EV/Sales ratio for Hologic, Inc. (HOLX)?
The 5Y average EV/Sales ratio for HOLX stock is 4.15x.
What is the 10Y average EV/Sales ratio for Hologic, Inc. (HOLX)?
The 10Y average EV/Sales ratio for HOLX stock is 4.50x.
What is the 15Y average EV/Sales ratio for Hologic, Inc. (HOLX)?
The 15Y average EV/Sales ratio for HOLX stock is 4.39x.
What is the 20Y average EV/Sales ratio for Hologic, Inc. (HOLX)?
The 20Y average EV/Sales ratio for HOLX stock is 4.41x.

Hologic, Inc. EV/Sales Ratio History

DATEEV/SALES RATIO
2026-04-074.25x
2026-04-064.25x
2026-04-024.23x
2026-04-014.22x
2026-03-314.22x
2026-03-304.22x
2026-03-274.23x
2026-03-264.23x
2026-03-254.22x
2026-03-244.22x
2026-03-234.23x
2026-03-204.21x
2026-03-194.21x
2026-03-184.20x
2026-03-174.19x
2026-03-164.20x
2026-03-134.20x
2026-03-124.20x
2026-03-114.21x
2026-03-104.22x
2026-03-094.22x
2026-03-064.23x
2026-03-054.23x
2026-03-044.23x
2026-03-034.22x
2026-03-024.22x
2026-02-274.21x
2026-02-264.20x
2026-02-254.21x
2026-02-244.21x
2026-02-234.21x
2026-02-204.21x
2026-02-194.20x
2026-02-184.20x
2026-02-174.20x
2026-02-134.19x
2026-02-124.19x
2026-02-114.20x
2026-02-104.20x
2026-02-094.19x
2026-02-064.18x
2026-02-054.17x
2026-02-044.17x
2026-02-034.17x
2026-02-024.18x
2026-01-304.19x
2026-01-294.19x
2026-01-284.30x
2026-01-274.30x
2026-01-264.30x
2026-01-234.29x
2026-01-224.30x
2026-01-214.30x
2026-01-204.30x
2026-01-164.29x
2026-01-154.29x
2026-01-144.30x
2026-01-134.28x
2026-01-124.28x
2026-01-094.28x
2026-01-084.28x
2026-01-074.29x
2026-01-064.29x
2026-01-054.28x
2026-01-024.27x
2025-12-314.26x
2025-12-304.27x
2025-12-294.26x
2025-12-264.26x
2025-12-244.26x
2025-12-234.28x
2025-12-224.29x
2025-12-194.29x
2025-12-184.29x
2025-12-174.29x
2025-12-164.29x
2025-12-154.30x
2025-12-124.29x
2025-12-114.28x
2025-12-104.28x
2025-12-094.29x
2025-12-084.28x
2025-12-054.29x
2025-12-044.28x
2025-12-034.29x
2025-12-024.28x
2025-12-014.28x
2025-11-284.29x
2025-11-264.28x
2025-11-254.28x
2025-11-244.28x
2025-11-214.26x
2025-11-204.24x
2025-11-194.25x
2025-11-184.24x
2025-11-174.33x
2025-11-144.33x
2025-11-134.34x
2025-11-124.36x
2025-11-114.36x
2025-11-104.34x
2025-11-074.33x
2025-11-064.33x
2025-11-054.34x
2025-11-044.33x
2025-11-034.33x
2025-10-314.32x
2025-10-304.32x
2025-10-294.32x
2025-10-284.33x
2025-10-274.32x
2025-10-244.33x
2025-10-234.32x
2025-10-224.32x
2025-10-214.32x
2025-10-204.21x
2025-10-174.09x
2025-10-164.02x
2025-10-153.94x
2025-10-143.87x
2025-10-133.85x
2025-10-103.98x
2025-10-094.03x
2025-10-084.01x
2025-10-073.98x
2025-10-063.95x
2025-10-034.00x
2025-10-023.99x
2025-10-013.94x
2025-09-303.96x
2025-09-293.94x
2025-09-263.95x
2025-09-253.87x
2025-09-243.90x
2025-09-233.97x
2025-09-223.95x
2025-09-193.90x
2025-09-184.01x
2025-09-174.00x
2025-09-163.73x
2025-09-153.76x
2025-09-123.79x
2025-09-113.90x
2025-09-103.85x
2025-09-093.92x
2025-09-083.91x
2025-09-053.92x
2025-09-043.90x
2025-09-033.89x
2025-09-023.91x
2025-08-293.94x
2025-08-283.91x
2025-08-273.92x
2025-08-263.91x
2025-08-253.94x
2025-08-224.01x
2025-08-213.94x
2025-08-204.03x
2025-08-193.98x
2025-08-183.95x
2025-08-153.98x
2025-08-143.99x
2025-08-134.05x
2025-08-123.99x
2025-08-113.99x
2025-08-083.99x
2025-08-073.99x
2025-08-063.93x
2025-08-053.98x
2025-08-043.99x
2025-08-013.94x
2025-07-313.92x
2025-07-303.92x
2025-07-293.98x
2025-07-283.96x
2025-07-254.00x
2025-07-243.98x
2025-07-233.97x
2025-07-223.94x
2025-07-213.84x
2025-07-183.86x
2025-07-173.86x
2025-07-163.85x
2025-07-153.82x
2025-07-143.90x
2025-07-113.96x
2025-07-104.02x
2025-07-093.97x
2025-07-083.91x
2025-07-073.88x
2025-07-033.91x
2025-07-023.94x
2025-07-013.94x
2025-06-303.93x
2025-06-273.92x
2025-06-263.92x
2025-06-253.88x
2025-06-243.91x
2025-06-233.89x
2025-06-203.89x
2025-06-183.86x
2025-06-173.87x
2025-06-163.93x
2025-06-133.90x
2025-06-123.93x
2025-06-113.89x
2025-06-103.93x
2025-06-093.89x
2025-06-063.88x
2025-06-053.81x
2025-06-043.78x
2025-06-033.81x
2025-06-023.75x
2025-05-303.76x
2025-05-293.80x
2025-05-283.85x
2025-05-273.76x
2025-05-233.32x
2025-05-223.33x
2025-05-213.35x
2025-05-203.44x
2025-05-193.44x
2025-05-163.46x
2025-05-153.40x
2025-05-143.38x
2025-05-133.48x
2025-05-123.57x
2025-05-093.46x
2025-05-083.42x
2025-05-073.38x
2025-05-063.25x
2025-05-053.23x
2025-05-023.31x
2025-05-013.48x
2025-04-303.53x
2025-04-293.54x
2025-04-283.53x
2025-04-253.52x
2025-04-243.54x
2025-04-233.53x
2025-04-223.53x
2025-04-213.46x
2025-04-173.50x
2025-04-163.43x
2025-04-153.51x
2025-04-143.57x
2025-04-113.51x
2025-04-103.47x
2025-04-093.60x
2025-04-083.55x
2025-04-073.71x
2025-04-043.69x
2025-04-033.73x
2025-04-023.67x
2025-04-013.72x
2025-03-313.74x
2025-03-283.71x
2025-03-273.77x
2025-03-263.72x
2025-03-253.68x

Showing the most recent 260 of 5,030 data points. The chart above shows the full history.

About Hologic, Inc.

Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.

Marlborough, MA
7,063 employees
Healthcare / Medical - Instruments & Supplies
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Paul Malenchini